These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12716812)

  • 1. Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
    Andersen S; Tarnow L; Cambien F; Rossing P; Juhl TR; Deinum J; Parving HH
    Diabetes Care; 2003 May; 26(5):1501-6. PubMed ID: 12716812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
    Andersen S; Tarnow L; Cambien F; Rossing P; Juhl TR; Deinum J; Parving HH
    Kidney Int; 2002 Jul; 62(1):192-8. PubMed ID: 12081578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme insertion/deletion polymorphism and diabetic albuminuria in patients with NIDDM followed Up for 9 years.
    Huang XH; Rantalaiho V; Wirta O; Pasternack A; Hiltunen TP; Koivula T; Malminiemi K; Nikkari T; Lehtimäki T
    Nephron; 1998 Sep; 80(1):17-24. PubMed ID: 9730698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate.
    Dragović T; Ajdinović B; Hrvacević R; Ilić V; Magić Z; Andelković Z; Kocev N
    Vojnosanit Pregl; 2010 Apr; 67(4):273-8. PubMed ID: 20465154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
    Schjoedt KJ; Lajer M; Andersen S; Tarnow L; Rossing P; Parving HH
    Scand J Clin Lab Invest; 2006; 66(3):173-80. PubMed ID: 16714246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.
    Jacobsen P; Rossing K; Rossing P; Tarnow L; Mallet C; Poirier O; Cambien F; Parving HH
    Kidney Int; 1998 Apr; 53(4):1002-6. PubMed ID: 9551410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensinogen T235 and ACE insertion/deletion polymorphisms associated with albuminuria in Chinese type 2 diabetic patients.
    Young RP; Chan JC; Critchley JA; Poon E; Nicholls G; Cockram CS
    Diabetes Care; 1998 Mar; 21(3):431-7. PubMed ID: 9540028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy.
    Tarnow L; Cambien F; Rossing P; Nielsen FS; Hansen BV; Lecerf L; Poirier O; Danilov S; Boelskifte S; Borch-Johnsen K
    Diabetologia; 1995 Jul; 38(7):798-803. PubMed ID: 7556981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.
    Schjoedt KJ; Andersen S; Rossing P; Tarnow L; Parving HH
    Diabetologia; 2004 Nov; 47(11):1936-9. PubMed ID: 15551047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study.
    Parving HH; Jacobsen P; Tarnow L; Rossing P; Lecerf L; Poirier O; Cambien F
    BMJ; 1996 Sep; 313(7057):591-4. PubMed ID: 8806248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy.
    Björck S; Blohmé G; Sylvén C; Mulec H
    Nephrol Dial Transplant; 1997; 12 Suppl 2():67-70. PubMed ID: 9269704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria.
    Rudberg S; Rasmussen LM; Bangstad HJ; Osterby R
    Diabetes Care; 2000 Apr; 23(4):544-8. PubMed ID: 10857950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal dose of losartan for renoprotection in diabetic nephropathy.
    Andersen S; Rossing P; Juhl TR; Deinum J; Parving HH
    Nephrol Dial Transplant; 2002 Aug; 17(8):1413-8. PubMed ID: 12147788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM.
    Penno G; Chaturvedi N; Talmud PJ; Cotroneo P; Manto A; Nannipieri M; Luong LA; Fuller JH
    Diabetes; 1998 Sep; 47(9):1507-11. PubMed ID: 9726242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/deletion polymorphism.
    Park HC; Choi HY; Kim BS; Kang SW; Choi KH; Ha SK; Lee HY; Han DS
    Kidney Blood Press Res; 2006; 29(4):216-24. PubMed ID: 16960460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Individual renal hemodynamic response to chronic angiotensin II receptor blockade and the influence on the renin-angiotensin system gene polymorphisms].
    Dragović T; Ajdinović B; Ilić V; Magić Z; Andelković Z; Kocev N
    Med Pregl; 2010; 63(9-10):630-7. PubMed ID: 21446090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
    Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The significance of deletion polymorphism in the ACE gene for progression of diabetic nephropathies treated with ACE inhibitors].
    Tarnow L; Parving HH; Jacobsen P; Rossing P; Lecerf L; Poirier O; Cambien F
    Ugeskr Laeger; 1998 Aug; 160(34):4886-9. PubMed ID: 9741257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of risk factors for the development of nephropathy in patients with IDDM: insertion/deletion angiotensin converting enzyme gene polymorphism, hypertension and metabolic control.
    Barnas U; Schmidt A; Illievich A; Kiener HP; Rabensteiner D; Kaider A; Prager R; Abrahamian H; Irsigler K; Mayer G
    Diabetologia; 1997 Mar; 40(3):327-31. PubMed ID: 9084972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of diabetic nephropathy in normotensive type 1 diabetic patients.
    Jacobsen P; Rossing K; Tarnow L; Rossing P; Mallet C; Poirier O; Cambien F; Parving HH
    Kidney Int Suppl; 1999 Jul; 71():S101-5. PubMed ID: 10412749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.